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Abstract
Background: Medical care of critically ill and injured infants and children globally should be based on best research
evidence to ensure safe, efficacious treatment. In South Africa and other low and middle-income countries, research is
needed to optimise care and ensure rational, equitable allocation of scare paediatric critical care resources.
Ethical oversight is essential for safe, appropriate research conduct. Informed consent by the parent or legal guardian is
usually required for child research participation, but obtaining consent may be challenging in paediatric critical care
research. Local regulations may also impede important research if overly restrictive.
By narratively synthesising and contextualising the results of a comprehensive literature review, this paper describes
ethical principles and regulations; potential barriers to obtaining prospective informed consent; and consent options in
the context of paediatric critical care research in South Africa.
Discussion: Voluntary prospective informed consent from a parent or legal guardian is a statutory requirement
for child research participation in South Africa. However, parents of critically ill or injured children might be
incapable of or unwilling to provide the level of consent required to uphold the ethical principle of autonomy. In
emergency care research it may not be practical to obtain consent when urgent action is required. Therapeutic
misconceptions and sociocultural and language issues are also barriers to obtaining valid consent.
Alternative consent options for paediatric critical care research include a waiver or deferred consent for minimal risk
and/or emergency research, whilst prospective informed consent is appropriate for randomised trials of novel therapies
or devices.
Summary: We propose that parents or legal guardians of critically ill or injured children should only be approached to
consent for their child’s participation in clinical research when it is ethically justifiable and in the best interests of
both child participant and parent. Where appropriate, alternatives to prospective informed consent should be considered
to ensure that important paediatric critical care research can be undertaken in South Africa, whilst being cognisant of
research risk. This document could provide a basis for debate on consent options in paediatric critical care research and
contribute to efforts to advocate for South African law reform.
Background
It has been observed that the need for intensive care is
increasing globally, with a disproportionate burden of crit-
ical illness in low and middle-income countries, where
access to intensive care is particularly limited [1]. A 2007
audit of intensive care services in South Africa highlighted
this injustice. The available public sector intensive care
unit (ICU) bed:population ratios varied from about 1:20
000 to 1:80 000 in different provinces [2] and there was a
further inequity between paediatric and adult ICU facilities,
with only 19.6 % of the nearly 4200 ICU beds in South
Africa dedicated to paediatric and neonatal patients [2].
It is accepted that the medical care of critically ill and
injured infants and children should be based on the best
available research evidence in order to optimise patient
outcome [3–9] and ensure rational and equitable use of
scarce resources [10]. However clinical research in this
population has been severely limited, particularly in low
and middle-income countries including South Africa,
due to both lack of prioritisation and concerns about
protecting vulnerable children from potential harm in
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clinical trials [11–14]. This has led to the situation where
some of the sickest, most vulnerable children are sub-
jected to the most anecdotally based medical practice,
including the use of untested, off-label or unlicensed
medications [5, 11, 15–17].
It is not appropriate to extrapolate the results from
animal and adult studies to determine appropriate paedi-
atric treatment, owing to pathophysiological, anatomical
and developmental differences amongst these groups
[12, 18]. The risks of harm and the need to protect
children have to be balanced against children’s consitu-
tional rights to the safest, most efficacious available
treatments, but this can only be determined by appro-
priate research [19–21], which requires reasonable
access to the research population [15].
In order for research involving children to be approved,
the child’s parent/s or authorised legal representative are
required to provide informed consent for their child’s par-
ticipation [11, 12, 22]. For a number of reasons which will
be explored in this article, obtaining comprehensive, vol-
untary prospective informed consent may be particularly
challenging in both emergency situations and paediatric
research [6]. When these circumstances combine, as in
paediatric critical care research; obtaining consent may be
even more difficult [6].
By synthesising and contextualising the results of a
comprehensive literature review, this paper describes the
underlying ethical principles and regulatory requirements
for paediatric critical care research in South Africa, the
potential barriers to obtaining written informed consent
in the context of a critically ill or injured child, and the
options for obtaining or not obtaining consent in this con-
text. It is hoped that this document could provide a basis
to stimulate debate around consent options in paediatric
critical care research and contribute to efforts to advocate
for South African law reform.
For the purposes of this paper, paediatric participants
refer to children from beyond the neonatal period to age
17; research risk refers to the potential that participants will
experience harm from participating in clinical paediatric
critical care research; harm refers to physical, psychological,
spiritual or social injuries, discomforts or inconveniences
[23]; and paediatric critical care refers to the health care of
children with life- threatening medical conditions and in-
juries, and after major surgery [24].
Discussion
Ethical principles and research risk
The Belmont Report describes three fundamental ethical
principles underpinning human research: respect for
persons, beneficence and its corollary non- maleficence,
and justice or fairness [3, 21]. Respect for persons in
turn incoporates the principle that individuals should be
treated as autonomous agents, and that persons with
diminished autonomy are entitled to protection [21].
Young children may lack decision-making capacity, and
are generally considered a relatively vulnerable popula-
tion, owing to their developmental and cognitive levels
and dependence on adults for care and protection [6, 12].
However, if one categorically protects this vulnerable
group from any risk of harm, all paediatric research is
effectively precluded. This is itself unethical as countless
future children would be denied potential research bene-
fits, including that of appropriate, evidence-based medical
care [5].
An example of the effect of over-protection from research
is evident in the current practice of administering drugs,
untested in the paediatric population, to critically ill infants
and children, thereby exposing patients to potentially harm-
ful medications as standard practice. A consequentialist
standpoint might allow almost any research where the
potential benefits for future patients (social value) out-
weighs the risks to individual participants, regardless of
risk level. This may, however, not be ethically justifiable, as
it potentially exposes the most vulnerable patients to high
risk of harm with no potential for individual benefit [23].
Ethical research can be conducted with vulnerable
populations, including children, provided additional
safeguards are in place to protect them from potential
exploitation and harm [9, 20, 21, 25]. These safeguards
include the “necessity” and “participant-condition” require-
ments, whereby the research cannot reasonably be per-
formed in a non-vulnerable surrogate population and the
participant must have the specific condition being in-
vestigated. Further safeguards, where possible, include
independent participation monitors, to monitor indi-
vidual children’s involvement, including changing risk
profiles and responses (physical and emotional), through-
out the research study; and independent consent monitors
to assess the quality of informed consent [25].
Both researchers and research ethics committees
(RECs) are obliged to protect child participants by mini-
mising associated research risks [5]. Accordingly, differ-
ent categories of research involving children have been
described according to risk levels [3, 12, 23] (Table 1). It
has been suggested that allowable research risk should
be positively correlated with the participants’ ability to
consent, and inversely proportional to vulnerability [26].
Therefore, the maximum research risk level to which
critically ill or injured children may be exposed is neces-
sarily lower than what would be allowed in adult partici-
pants [5]. In the United States, this threshold is set at
“minor increase over minimal risk” (Table 1) [5].
The United States Common Rule presents minimal
risk as when “the probability and magnitude of harm or
discomfort anticipated in the research is not greater in
and of themselves than those ordinarily encountered in
daily life or during the performance of routine… tests” [20].
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There are a number of problems with this definition,
including different standards for what constitutes “daily
life” - a child in a violent, gang-ridden community in
South Africa, for example, will be exposed to greater daily
risks than a child living in a higher socioeconomic envir-
onment with less crime. A detailed discussion of these is-
sues is beyond the scope of this paper. Nevertheless, if we
use the definition above, virtually no studies comparing
drugs, devices, or other critical care interventions would
ever qualify as minimal risk [27].
We agree with previous authors that instead of evalu-
ating the absolute risks of research, the incremental risks
of research interventions should be judged above the
risks the patient would experience as part of routine
clinical care, as the daily life standard equivalent [7, 27, 28].
This approach would allow important paediatric critical
care research to be conducted without unnecessary restric-
tions and bureaucracy [27] and is supported by the Com-
mon Rule statement that independent review boards
should only evaluate those risks and benefits that may
result from the research itself [20]. This requires careful
separation of the risks of study interventions and those
inherent to the condition being managed [5, 7].
Similar to clinical decision making processes, any
research interventions for which the incremental ben-
efits equal or exceed the risks are considered ethically
acceptable [5, 29]. In some cases a small net risk may
be allowable in order to generate knowledge to bene-
fit future patients [5, 25].
In order to fully assess risk and benefit, researchers
should distinguish between therapeutic and non-therapeutic
research procedures [30, 31]. Therapeutic procedures,
such as specific ventilation strategies or administra-
tion of medications, have the potential to benefit the
study participant, but may also introduce harm. Non-
therapeutic procedures, such as downloading data from
monitors, are performed solely to answer the research
question and the participant does not stand to directly
benefit from these procedures, although the generated
knowledge could inform clinical practice as well as fu-
ture clinical trials, thus potentially benefiting future
patients [3, 7].
In studies of therapeutic procedures the standard of
clinical equipoise must be met. This requires that the
research intervention be consistent with competent clin-
ical care and that a genuine state of uncertainty exists
amongst the expert medical community as to the pre-
ferred treatment [3, 7]. Sometimes the requirement for
equipoise might hinder important research to confirm
the efficacy of current (but unproven) treatments. For
example, the Fluid Expansion as Supportive Therapy
(FEAST) Trial, in which over 3000 critically ill children
were randomised to different fluid resuscitation strat-
egies [32], was challenged with regard to the presence of
initial equipoise. Most clinicians from developed coun-
tries would present fluid boluses as the treatment of
choice for shock in children, although this was not local
standard practice, and the trial authors argued that there
was insufficient evidence for fluid resuscitation of children
with shock or life-threatening infection in resource-poor
settings [33]. The trial was eventually able to report the
surprising finding of a significant increase in the risk of
dying in those who had received the fluid boluses com-
pared to controls [32, 33]. These important, if controver-
sial, findings would never have been identified if the trial
had not been conducted due to apparent lack of equipoise.
Non-therapeutic interventions in paediatric critical care
research can only be justified if they fall into one of the
first two categories outlined in Table 1 [3]. However, it is
sometimes difficult to distinguish between therapeutic and
non-therapeutic research, e.g. therapeutic research may
have many associated non-therapeutic interventions, such
as blood draws for research purposes. The term “thera-
peutic” in itself may be misleading in the presence of clin-
ical equipoise where a trial of a new therapy or medication
offers only the potential for therapeutic benefit, at best. It
is therefore suggested that, when evaluating research pro-
tocols, RECs consider the associated risk categories of the
research as more important than the distinction between
therapeutic and non-therapeutic research [34].
Legal and regulatory issues in South Africa
Under South African law, children under 18 years of age
are considered minors [35] and therefore unable to act
Table 1 Categories of research risk [3, 12, 23]
Research category Benefit Example
1. Not greater than minimal risk interventions ● Unlikely to be individual benefit Additional testing on routinely
collected specimens
● Likely to yield generalisable knowledge
2. Interventions posing minor increase over minimal risk ● No direct benefit to individual child participant Drawing blood for analysis
● Likely to yield generalisable knowledge
3. Interventions posing greater than minimal risk ● Possibility of direct benefit to individual child
participant
Clinical drug trials
● Will yield generalisable knowledge
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independently without assistance from parents or legal
guardians [36]. However, there are many legal discrepan-
cies on when children evolve the capacity to make deci-
sions for themselves. The amended Children’s Act No 38
of 2005 has attempted to resolve some of these [35]:
children judged to have sufficient maturity and mental
capacity can now consent to, amongst others, medical
therapeutic procedures; human immunodeficiency virus
(HIV) testing; and contraceptive use from the age of
12 years [35]. There are no clear legal statutes specifying
when children can independently consent to participation
in human research studies, but ethical norms require par-
ental consent and, where possible, child assent for all
children under 18 years of age [36].
In 2012, Section 71 of the National Health Act 61 of
2003 came into effect in South Africa, introducing new
requirements for health research involving minors, includ-
ing the requirement for written consent from parents or
guardians for all research; that “therapeutic research” must
be in the best interests of the participant; and that minis-
terial consent must also be obtained for all “non- thera-
peutic research” [37]. The revised Act was promulgated
without accompanying guidelines or regulations for how
ministerial consent was to be obtained and the new legal
requirements were in conflict with the 2004 National
Department of Health Research Ethics Guidelines [38].
Many South African RECs therefore continued procedures
in accordance with the 2004 Department of Health
Research Ethics Guidelines [38]. These guidelines state
that research on children should be of minimal risk only,
that consent from the parent or legal guardian is required
in all but exceptional circumstances (such as emergen-
cies), and consent is also required from the minor where
possible [39]. In October 2014 ministerial consent was of-
ficially delegated to RECs registered with the National
Health Research Ethics Council [40]. Interestingly, the
South African Good Clinical Practice (GCP) Guidelines
and the national Human Sciences Research Council
(HSRC) guidelines allow a child’s “caretaker” to provide
consent for their participation in research [41, 42]. This
acknowledges the many South African children who are
raised and cared for by people other than biological par-
ent/s or legal guardians, often by an informal arrange-
ment; however this provision is in direct conflict with the
National Health Act 61 of 2003 [34]. Clearly there is an
urgent need for alignment between the National Health
Act and other South African research guidelines in order
to ensure both legally and ethically acceptable practice by
RECs and researchers.
Barriers to obtaining informed consent for paediatric
critical care research
Throughout the world, it is generally accepted that obtain-
ing informed consent from a parent or legal guardian for
their child to participate in paediatric research is necessary
in order to protect the child from potential research-
related harm and to protect parental autonomy [43].
Valid informed consent consists of three major elements:
1) adequate disclosure of information, which requires suffi-
cient time; 2) adequate participant or proxy understanding
of information received; and 3) voluntariness of the deci-
sion; without real or perceived threat or coercion, either
explicit or implicit [44–47]. All three of these requirements
may be threatened in the paediatric critical care context as
it may be impractical to obtain informed consent; the valid-
ity of consent may be questionable; sociocultural barriers
may impact on the ability to obtain consent; and the poten-
tial for therapeutic misconception is particularly high.
Obtaining informed consent may also at times do more
harm than good. These issues are discussed below, and the
relevance to the South African context is highlighted.
Impracticability
In paediatric critical illness research, a parent or legal
guardian’s absence or the need for urgent action may
not provide the time needed for informed consent to be
obtained prior to the research intervention, for example
in resuscitation research [6, 13, 18, 26]. In such cases it
might in fact be harmful to delay the research interven-
tion in order to obtain consent [11]. In the context of
emergency research in child victims of trauma (e.g. fires,
motor vehicle accidents), which is very common in South
Africa and other low and middle-income countries [48],
the parent may have also been injured, or even died, in
the incident, substantially impacting on the likelihood of
informed consent and attaining recruitment goals.
A rural Ghanian genomics study (“MalariaGEN”) high-
lighted the complexity of seeking consent in emergency
research situations. Children admitted to hospital with
severe malaria, needing urgent and rapid medical treat-
ment, were recruited as cases into the study. However,
after recruiting initial cases, researchers felt that it was
“practically impossible and ethically inappropriate to
conduct a detailed consent process for research before
collecting the samples needed for diagnosis and treat-
ment” [49].
Validity of consent – situational incapacity
“…you know being only one head my heart was shaken
about how the child was… that’s why [my head] didn’t
grab many things”. Quote from a mother of a child
enrolled in the Fluid Expansion as Supportive Therapy
(FEAST) study [50].
Paediatric critical care services provide care to children
with life-threatening medical and surgical conditions, and
may involve care in a complex environment with state-of-
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the-art equipment. Critically ill children and their immedi-
ate families may be far removed from their traditional
support structures for political, financial, or other reasons.
This is particularly true of South Africa’s large migrant
community.
Even in the best, most well resourced environments,
having a child with severe illness or injury is extremely
(dis) stressful for the child, parents and extended family
[24, 51–53]. The illness often evolves rapidly, leaving lit-
tle time for parents to assimilate the implications of
their child’s disease before they may be approached to
provide consent for both clinical procedures and research
[3]. A number of studies suggest that the paediatric inten-
sive care unit (PICU) environment is more stressful than
that of a general paediatric hospital ward, and that the
needs of parents and their critically ill infants and children
are unique and different from those in neonatal or adult
intensive care units [54–59]. Stress is defined here as
“circumstances which place physical or psychological
demands on the individual and the overall emotional
reactions experienced by the individual or family” [60].
Parents of critically ill or injured children may be unable
or unwilling to prioritise information about a research
study over concern for their child’s immediate welfare.
Studies have shown that even competent adults may not
completely understand the research for which they have
given consent [61–63]. The emotional and psychological
burden on parents of critically ill or injured children may
impair their capacity for rational informed decision mak-
ing, including decisions relating to research [6, 11, 13, 53].
Parental anxiety (being “too stressed” or “overwhelmed”)
has been reported to be the most common reason for
declining participation in clinical PICU research [54, 64].
Some identified stressors include changes in the child’s ap-
pearance; life support equipment and monitors (with
associated alarms); nursing procedures; fatigue; poor
nutrition; lack of diurnal rhythms; and communication
barriers between parents and healthcare staff [24, 65, 66].
A positive correlation between parental anxiety and
the number of invasive procedures has been reported,
which relates to acuity of illness [24, 51]. It has also been
shown that parents of children admitted as emergencies
have higher levels of stress than of those admitted elec-
tively [67], with higher consent rates in parents of children
undergoing planned surgery than emergency admissions
[64]. This is important in the context of a developing
country such as South Africa, where the majority of PICU
admissions are emergencies, mainly for the management
of severe infectious diseases [10].
The “FEAST” trial incorporated a qualitative sub-study
to investigate the consent process [50, 68]. This sub-
study suggested that being asked to make choices about
research at the time of admission of a critically ill child
might cause harm by “raising concerns and doubts at a
time when parents are unable to listen, ask, understand,
or challenge those that they are seeking help from” [50].
Results suggest that some parents may be completely
unable or unwilling to assimilate study information, with
many parents reporting that they could not remember
anything they had been told about the trial, and even
that they were “not listening to anything” whilst receiv-
ing study information [50]. Only 18 % of parents inter-
viewed fully recalled the nature of the research they had
agreed to their child participating in [50].
Vulnerability refers to an inability to protect oneself,
due to intrinsic and situational factors that threaten vol-
untary choice [25, 69]. In this context, the critically ill or
injured child’s parents and family should also be seen as
being vulnerable [18, 53]. Parents are required to make
decisions for their child at a time of intense emotional
stress, in a foreign environment [70] with the potential
for perceived coercion (for example if the parent fears
his/her child’s quality of care is contingent on participa-
tion in a trial), undue inducement and exploitation.
In many cases, therefore, it may be impossible and/or
inappropriate to obtain, or attempt to obtain complete
voluntary, informed consent for research participation in
the context of a critically ill or injured child, owing to
situational incapacity of the parent at a time of intense
emotional stress. This situational incapacity could be a
potential justification for considering alternative consent
models [6].
Where possible, the research consent process should
start before admission [11] when the parent is emotionally
stable, but this is only feasible for elective admissions, for
example for children admitted to intensive care units fol-
lowing surgical correction of congenital heart defects [71].
This approach is similar to that used in neonatal research
where parents may be informed antenatally about poten-
tial recruitment of their newborn in emergency research,
and are provided with the option of opting out (declining)
at a time of relative emotional stability [72]. Elective ad-
missions constitute the minority of South African PICU
admissions [10]; therefore a pre-admission consent model
would only be appropriate or possible in specific research
contexts.
“First do no harm”
Health care providers have an obligation to relieve and
prevent suffering of patients and their relatives. The added
burden for parents of being approached to provide con-
sent for research as well as consent for clinical care at a
time of intense stress, has been discussed previously
[43, 50, 54, 68, 73]. Ethically, respect for persons (includ-
ing parental autonomy) must be respected and the safety
of the child-patient must be ensured, which includes safe-
guarding against the potential negative effects of decision-
making in a highly stressful medical environment [43].
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The requirement for consent may also add strain on
patient (parent)/clinical healthcare provider relation-
ships. For example, nurses responsible for patient clin-
ical care may not be able or allowed to provide directive
advice about study enrolment or procedures, particularly
in a high-acuity emergency situation [50].
A study of parents’ perspectives on consent approaches
for minimal risk research in hospitalised children reported
an increased level of anxiety as a negative effect of a writ-
ten consent approach; and also reported that having to
sign a consent form resulted in the research being per-
ceived as being more risky than when verbal consent was
requested [74].
In this context, the burden (in terms of increased anx-
iety) to the parent of being asked to consent to their
child’s enrolment in low risk research may be seen as
introducing harm, without adding to the benefits of the
research.
Sociocultural issues
In some non-Western cultures, including traditional
African cultures, it may not be considered appropriate
to obtain individual informed consent [75–77]. Gender
and generational hierarchies inform family decision-
making in many South African communities. In some
cases women may not have societal authority to make
independent decisions for their children, instead requir-
ing assistance and agreement from other family mem-
bers, including the husband (father) and the child’s
grandparents [78]. If the parent so wishes, it might
therefore be more respectful to inform the extended
family and/or community about the research, with the
ultimate decision about participation still made by the
legal proxy as required by South African law [77]. This
again requires time, which might not be available given
the child’s severity and acuity of illness.
Cultural norms and behaviours may also threaten the
validity of consent. For example, people from some
cultural backgrounds in South Africa might respond
with an affirmative to any question requiring choice.
Although this might indicate understanding, in some
cases it merely indicates respect for the person in
authority – acknowledging a lack of understanding
might suggest that the researcher had not provided
adequate explanation, which could be seen as being
disrespectful [77].
The MalariaGEN study also reported that having a
well-written consent form does not guarantee under-
standing, especially in populations with high levels of
illiteracy and where indigenous languages do not
include research-related terms. In such situations par-
ents may rely on verbal explanations during the con-
sent process [49].
Therapeutic misconception
Research, which aims primarily to generate generalisable
knowledge for future patients, should be distinguishable
from clinical care, which is focused on providing benefit
to individual patients [3, 79]. Failure to understand the
distinction between research and clinical interventions is
termed “therapeutic misconception”, and could lead to
questionable or invalid consent [53, 80].
Examples of therapeutic misconceptions include the
belief that randomisation is a way of rationing access to
scarce or expensive medical technologies; that the child
participant would always directly benefit from the re-
search interventions; and that participation ensures access
to certain medications or therapies not otherwise
available, despite potential randomisation to placebo
arms [3, 11, 17, 50, 53, 80–85]. Parents of children
with life-threatening illness or injury may be more
likely to consent to participation in clinical trials in
the hope of finding a “miracle cure” [86].
Parents of critically ill or injured children usually have
to fill in a number of consent forms for clinical proce-
dures. In South Africa and other low and middle-income
countries, these include consent for surgery, blood admin-
istration, HIV testing, use of restricted medications, and
vascular access procedures. In this context it is challenging
to ensure that parents completely understand whether
consent is being given for normal therapeutic activities or
research. A study of consent options for paediatric critical
care research reported that 16 % of parents were unlikely
to properly read a research-related hand-out because they
felt overwhelmed by the sheer volume of papers they had
received [87].
There may also be confusion and the potential for un-
due influence when clinician-researchers fulfill a dual role
[3, 83, 88]. It has therefore been suggested that an inde-
pendent third party should explain the research and
obtain informed consent [3], although this might also have
drawbacks in having an unknown person approach the
parent at an emotionally vulnerable time. Informed con-
sent forms should avoid using terms that might aggravate
therapeutic misconception such as “doctor”, “treatment”,
and “medication” [79].
In certain cases the term “misconception” is a mis-
nomer, as children enrolled in some clinical trials may
actually receive better care than those not enrolled. A
number of clinical trials in Africa have reported that
critically ill children enrolled in trials were more fre-
quently assessed, had closer monitoring, and parents did
not have to pay for some aspects of their care, which
would have been required if the child were not enrolled
[50, 89]. Indeed, in some poorly resourced settings, clin-
ical trials provide the only access to quality health care
services for the local population [90]. Patient outcomes
for children enrolled in both the therapeutic and control
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groups of clinical trials have been noted to be sub-
stantially better than the expected outcome for chil-
dren admitted with the same medical status outside
the trial [89, 91].
Informed consent – principles and options
“…it is dangerous to let one moral principle – informed
consent – become absolute” - M. Bland, 1997 [92].
Respect for autonomy is often considered the most im-
portant ethical principle in medical research ethics [93].
Informed consent aims to ensure respect for participant
autonomy by promoting choice based on individual
values, to avoid participants being used merely as a means
to an end. This is particularly important in a situation
where researchers’ interests may differ from the aims of
clinical care [45, 79]. Informed consent is not just obtain-
ing a signature on a form, it is a process of information
exchange between the investigator and potential partici-
pant, with the latter receiving enough information to be
able to make voluntary, fully informed decisions about
whether or not to participate [3, 79, 94, 95]. Specific com-
ponents of the informed consent process have been out-
lined previously [94].
Most critically ill children cannot be considered autono-
mous, as they are incapable of understanding, communi-
cating and/or making meaningful choices or decisions
[93]. The principle of respect for participant autonomy
may, therefore, not be directly applicable to these children
[93], but the overriding principle of respect for persons
holds [21].
It has been suggested that in order to properly protect
children in paediatric critical care research, the primary
emphasis on respect for parental autonomy (and therefore
informed consent) should be replaced by a focus on the
other ethical principles of beneficence, non-maleficence,
and justice, whilst maintaining respect for the child’s
developing or future autonomy [5, 26, 43, 93]. Non-
maleficence includes limiting or preventing physical and
psychological threats, for example by minimising research
risks [5, 43]. The South African Constitution states, ‘a
child’s best interests are paramount in every matter con-
cerning a child’ [96]. Acting in the child’s best interests
involves the combined principles of beneficence and non-
maleficence [93], and these principles are supported by
local RECs’ essential role in filtering out research protocols
with an unacceptable risk: benefit profile so that parents are
only asked to consider participation in appropriately vetted,
safe studies (the Nuffield “fair offer” concept) [97, 98].
RECs should therefore initially act in loco parentis by
only approving those studies that the most conscientious
parent would agree to [97, 98], as well assuming a
parens patriae role in protecting those who cannot
protect themselves [31]. In this way, RECs can ensure
that important paediatric research proceeds appropri-
ately and with sufficient protection of vulnerable partici-
pants, regardless of whether parental consent can be
consistently or adequately obtained. It has, however, also
been argued that research governance may be overly
restrictive and paternalistic. In the case of severe paedi-
atric disease, parents may allow their children to partici-
pate in trials despite high levels of risk, and may even
see this as a right [99]. In order to prevent RECs from
acting as the sole arbiter of what is in the participants’
best interests, community consultation or collaboration,
including parents of previously critically ill children,
medical professionals and REC members, for example, is
recommended to ascertain what could be considered
acceptable levels of risk.
Chapter 9 (section 71) of the South African National
Health Act 61 of 2003 presents consent to participation
in research as a statutory imperative, and does not allow
for deferred or waived consent under any circumstances
[34, 37]. South African law does not, therefore, adequately
address the complex ethical and procedural issues relating
to paediatric critical care research, and should be chal-
lenged as such.
Blind adherence to the legislative and ethical doctrine
of informed consent, without true consideration for the
underlying ethical principles of beneficence and respect
for individual autonomy, may promote deceitful or inad-
equate consent mechanisms, which are not in research
participants’ best interests [45]. Attempting to obtain in-
formed consent where it is largely impossible is demora-
lising and threatens the integrity of the researcher, REC
and the institution [45]. Considering options other than
prospective, informed consent in carefully selected cases
along with appropriate local REC oversight and research
risk reduction, may be ethically preferable [83].
If alternatives to the prospective informed consent
model are never considered, many important studies
could not feasibly be conducted, and unproven therapies
would continue to be used in the care of critically ill and
injured children. By considering alternatives and challen-
ging restrictive legislation, South African RECs would be
fulfilling their role as advocates for vulnerable child-
participants and their parents [53].
Options for consent
Prospective informed consent
It is generally agreed that all studies of novel investiga-
tional drugs, devices or biological agents require com-
prehensive, voluntary, prospective informed consent
[13]. Randomised controlled trials often compare the
best standard treatment with a new treatment, which it
is hoped might be more effective. The new treatment,
however, might also be less or equally effective, and it
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may be associated with unacceptable adverse events.
Parents should be informed of all possible risks and ben-
efits, even if doing so raises anxiety and adds stress [53].
Children require permission from a parent or legal
guardian to participate in clinical trials [22, 35, 36]. This
depends on the concept that parents are best placed to
make medical decisions for their children, which is not
always the case [12, 23, 93]. In order to make decisions
for their children, parents or legal guardians should
ideally display commitment to the child’s best interests;
adequate knowledge and information; emotional stabil-
ity; and the ability to make reasoned judgements [100].
Only a parent with decisional capacity can give truly
informed consent [22].
Even if the parent has sufficient capacity, parental
choice cannot reflect the views of a young child or infant
- at best it reflects parental discretion and family values
[53]. Therefore, assent should be sought wherever pos-
sible in awake, aware children of sufficient age and devel-
opmental level to understand basic research concepts and
implications [12, 21, 42, 101, 102]. The assent process is a
way of appropriately engaging with the child about his/her
participation in research, thereby showing respect for their
developing autonomy and sense of self-worth [103]. Real-
istically, obtaining assent is seldom possible in the critical
care environment but whenever possible, assent should be
taken in a developmentally appropriate manner [22] and
may require alternative communication methods in venti-
lated children, for example. The assent process may give
the child a sense of control over their own bodies and a
voice in a situation where they often have none [12].
Dissent should always be respected for research participa-
tion, regardless of parental consent, for all children with
sufficient developmental levels of understanding and
decision-making ability [5, 22, 25].
Where prospective informed consent is required and
appropriate, this should involve both a verbal and writ-
ten or otherwise recorded communication process,
ideally in the parent or legal guardian’s home language
[82]. Careful reading of shorter, simplified forms, written
at a suitable reading level, has been shown to enhance
understanding [79, 87, 104–106].
Assessing parental understanding is fundamental to
the informed consent process, and can be done using
open-ended questions after comprehensively describing
the research, such as, “how will being part of this study
help your child?” Leading and closed-ended or yes/no
questions, such as, “do you understand what this research
is about?” should be avoided [25, 107].
It is recommended that where prospective informed
consent is required by the local REC, the quality of con-
sent (capacity, voluntariness, understanding) be assessed
or confirmed by independent consent monitors, wher-
ever feasible [25, 44, 108].
Waiver of individual consent, deferred consent, and
“blanket assent”
“When a child arrives there, let him/her be treated
first and then later let [the parents] be asked the
questions”. Quote from parent of child participant in
the Fluid Expansion as Supportive Therapy (FEAST)
Trial [50].
Research in the context of critically ill or injured
children may be considered ethically justifiable without
prospective voluntary informed consent if it has the
potential to benefit the population by producing sound
evidence or a better understanding of best treatment
(i.e. is important, relevant and scientifically sound),
and/or where the intervention has only minimally in-
creased risk in the context of the child’s underlying
condition [6, 27].
Waiver of prospective informed consent
The United States Common Rule states that an ethics
review board may waive the need for informed consent
if the research involves no more than minimal risk to
participants; the waiver would not adversely affect the
rights and welfare of the participants; the research could
not practically be carried out without the waiver; and,
whenever appropriate, participants would be provided
with pertinent information after participation [20]. Other
groups have provided similar guidelines [109].
A systematic review of 11 paediatric studies focussing
on clinical research without prospective consent sug-
gested general support for waiver of consent in acute
care research [13]. However, providing no study infor-
mation to the parent precludes the option of opting out,
and thus ignores the many reasons why a parent would
not wish their child to participate in a clinical study [13].
Waiving the need for informed consent may diminish
parental autonomy and undermine public trust in the
healthcare service and clinical research [50], however
this model might be appropriate for very low risk studies
such as folder reviews, observational studies of standard
practice with non-invasive outcome measurement, and
practice improvement initiatives [50, 110].
A paediatric emergency resuscitation study, involving
a trial of brain cooling after in-hospital arrest, reported
that the majority of parents supported the research
occurring with a waiver of prospective informed con-
sent, as long as they were aware of the research study
in progress and had the opportunity to “opt out” [87, 111].
Parents also endorsed a community consultation process
for paediatric critical care research [87]. Families of chil-
dren sharing a particular disease, including the experience
of critical illness or injury, form a meaningful community
[88, 112]. Therefore appropriate community consultation
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could include dissemination and display of research infor-
mation, such as brochures and posters, within existing sup-
port and information-sharing groups of parents of critically
ill or injured children. These materials should summarise
the purpose, risks and benefits of the study/studies being
conducted in the unit; state that no formal individual con-
sent would be sought; present ways to opt out of the re-
search; and direct parents to the contact person should
they have questions or to give feedback [112]. Such a
“blanket assent” approach has been shown to be effective
and acceptable to parents in a prospective drug trial for
paediatric cardiopulmonary arrest, with 81 % of parents be-
ing aware of an ongoing trial and only 9 % indicating that
they would not want to participate [112].
Transparency and communication are essential com-
ponents in creating trust and protecting autonomy. All
reasonable efforts should be made to maximise commu-
nication with research participants and their families in
as timely a fashion as possible [87], while being respect-
ful of not over-burdening parents with unnecessary or
inappropriate information. In this context, “saturating”
the hospital environment with information about on-going
research studies may reduce anxiety and improve under-
standing and trust [87]. High illiteracy levels in the South
African context may limit the efficacy of this approach and
alternatives using verbal communication, such as focus
support and information sharing groups, should be consid-
ered in addition to written material.
Critical care audits and practice improvement initiatives
Critical care audits and practice improvement initiatives
are gaining popularity as an evidence-based approach to
improving the care and outcomes of critically ill and injured
children. An example is the implementation of practice
“bundles” and continuing audit to reduce the incidence of
hospital-acquired infections in PICU, as undertaken by the
Institute for Healthcare Improvement (http://www.ihi.org/
Engage/Initiatives/Completed/5MillionLivesCampaign/
Pages/default.aspx).
It is generally accepted that these initiatives should
form part of clinical practice; but when the results are
sufficiently important to warrant dissemination, ethical
regulations, particularly the requirement for prior review
and informed consent, may appear unnecessarily restrict-
ive. The concept of “learning health systems” has therefore
been proposed [113], in which high-quality patient care is
combined with routine data collection, without systemat-
ically modifying therapy for the purpose of developing
generalisable knowledge [113]. This blurs the distinction
between practice and research, which has been upheld
since the Belmont Report [21]. “Learning health systems”
might be particularly important in resource-limited coun-
tries such as South Africa, where identification of which
aspects of critical care management impact on patient
outcomes can inform appropriate utilisation of scarce hos-
pital resources. Unnecessary regulatory burdens could
impede this process, with potential negative consequences
to patients.
Obtaining informed consent from every child admitted
to PICU is not practical, and even if sought, missing data
from those unable to provide consent for involvement in
practice improvement initiatives could substantially skew
the data. Waiving consent is justifiable in this context as
no experimental intervention is assigned, so everything
studied could be seen to fall under standard medical
care, with no added risk [113]. It is generally accepted
however, that even if formal consent is not sought, par-
ents should be informed about on-going projects [113],
for example by focus group discussions, posters, and dis-
semination of brochures, as mentioned previously [114].
Deferred consent model
“In my case it was after my child felt better the
following day before they came and had the
discussions with me. If the girl [project staff] had come
on the day I brought the child I could not have
listened to her”. Mother of participant in the
MalariaGEN trial [49].
If one accepts that informed consent is often not truly
possible in the paediatric critical care context, obtaining
approval in principle (assent) would allow informed
consent, when needed, to be deferred and the process
continued until parents are available and/or compe-
tence is achieved [6]. This is the model for deferred,
or continuing consent: a child is enrolled in a study,
preferably with limited explanation and verbal assent;
but informed consent for continued enrolment in the
study is deferred until the child has stabilised and/or
the parent or guardian is able to assimilate study informa-
tion sufficiently to make an informed decision [6, 50]. Ini-
tial assent refers to an affirmative agreement indicating
some level of understanding and decision making ability,
and essentially provides a quick opt-out option before
study interventions are performed [50]. There is currently
insufficient empirical evidence on whether it is preferable
to provide limited study information in an initial assent
process, or rather to completely defer all information and
obtain consent to use data already collected only once the
child’s condition has stabilised and/or the parent has
regained capacity.
Deferred consent, as used in the “FEAST” and
“MalariaGEN” trials, might be useful in emergency sit-
uations where urgent action is required and prospective
informed consent is not reasonably practical [6, 49, 50, 68].
Item 30 of the Declaration of Helsinki (2013) approves the
concept of deferred consent if the legally authorised
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representative is not available and the research cannot be
delayed. “The study may [then] proceed without informed
consent…[and] consent to remain in the research must be
obtained as soon as possible” [9]. The concept of deferred
consent in critical care research is generally supported by
parents and clinical and research staff [49, 50, 115].
Further ethical dilemmas arise when an enrolled child
dies before deferred informed consent can be obtained:
Should bereaved parents be approached for consent after
the child’s death and should their collected data be
included in the analysis [11]? Excluding data on children
who die before consent can be obtained could introduce
systemic bias; reduce statistical power; decrease external
validity; and skew randomisation, thus threatening scien-
tific validity of the study [11, 95, 116, 117]. The intention
to treat principle also requires that all randomised par-
ticipants be included in the primary analysis [95]. A ran-
domised controlled trial of critically ill adults found that
when participants without deferred consent were excluded
from analysis, there was no treatment effect (p = 0.35), but
this became significant (p = 0.006) when all participants
were included [116]. Thus, not including those without
complete deferred consent could cause harm by decreas-
ing study validity [116, 117]. This could be considered un-
ethical and unjust to those participants who were enrolled
in the trial with consent [116].
Confronting recently bereaved parents with requests
for deferred consent could unjustifiably add harm by in-
creasing parental distress with no possible benefit to the
child participant [95, 118]. Furthermore, the high emo-
tional stress levels of a recently bereaved parent might
again render them situationally incapacitated, which
would make it inappropriate to approach them for in-
formed consent at that time [95].
The “FEAST” trial did not seek consent for included
children who died in order to reduce parental self-blame
[50, 68]. Diverse staff interviewed generally felt this
approach was humane and appreciated, but the need for
further discussion and reflection, including in-depth
consultation of community members, was noted [50].
Another study in a different context reported that two
thirds of parents of deceased children would want to be
informed about the trial they had been enrolled in [115].
There may be a large distinction between being informed
of a study and providing comprehensive informed consent
after the event. On consideration of the risk: benefit bal-
ance, it is suggested that clinical data collected on children
who die before deferred consent has been obtained should
be included, as long as confidentiality and privacy require-
ments are met [95, 117, 118].
Research ethics committees should assess trial proto-
cols individually to determine the appropriateness and
methods of using deferred consent. This process should
ideally also be informed by community consultation with
parents of children who have received or are receiving
critical care; by asking them hypothetically whether they
found the proposed study and consent method accept-
able [87, 88, 112]. It is further recommended that empir-
ical research involving bereaved parents be conducted in
South Africa in order to objectively inform consent
models in this context.
Comparative effectiveness research
In the absence of good evidence about which competing,
but generally accepted therapy or equipment is best,
many clinicians choose care practices on the basis of ad-
vertising, local custom and personal preference [119].
This can lead to harm by administering untested and
unproven interventions [113]. The premise behind com-
parative effectiveness research, often using interventional
randomised controlled trial designs, is that being assigned
to either treatment group exposes no additional risk to
the patient, assuming both fall within the range of
standard clinical practice. This is different from the in-
herent risk of being randomised to the experimental
arm of a trial assessing a novel intervention [119]. In
comparative effectiveness research, any incremental
risks would arise from nontherapeutic trial procedures,
which are usually limited to recording clinical data and
analysing biological samples. Therefore, these studies
generally only pose minimal risk [7] and may even be
considered as such when testing two drugs (assuming
both drugs could have been routinely given as part of
standard care). Cluster-randomised trials are often used
in comparative efficacy studies, with interventions deliv-
ered across an entire unit or institution. This makes
obtaining individual informed consent impossible in
some cases, although permission to use the data can
generally be obtained, along with information dissemin-
ation using methods outlined above [27].
Summary
The primary ethical responsibility in paediatric critical
care research is to protect this vulnerable population from
exploitation and harm. However, there may be considerable
harm arising from the sometimes-restrictive ethical re-
quirements imposed by RECs according to current South
African laws and norms. These requirements, specifically
those demanding informed consent in all situations,
although meant to ensure protection, may be impractical,
inappropriate, or even impossible to correctly obtain.
It is our contention that parents and legal guardians of
critically ill or injured children should only be approached
for consent to participate in clinical research when it is
ethically appropriate to do so [95]. South African RECs
should, therefore, be permitted to consider alternatives to
prospective informed consent where it is in the best inter-
ests of participants and their parents, and/or without
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which important research might not be able to be under-
taken, whilst being cognisant of the risk levels of the pro-
posed research. There also needs to be an appreciation
that even some randomised controlled trials might afford
minimal incremental risk to participants. Alternative con-
sent options include waived or deferred consent when the
research is of emergency care and/or the parent is incap-
able of providing fully informed consent owing to high
levels of distress [50, 68].
The challenges endemic to research in the paediatric
critical care population warrant the development and
amendment of specific South African regulations and
guidelines to clearly define the conditions under which
research can legally, ethically and realistically be con-
ducted without prospective informed consent [45, 120].
This process should be informed by local empirical
research and community consultation. Having clear and
consistent guidelines would facilitate local REC deliber-
ation and consensus; enhance research integrity; and
show a clear way forward for paediatric critical care
research in South Africa.
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